Sandoz Group AG (SDZNY) Research
Sandoz Group AG operates as a global pharmaceutical enterprise, primarily focusing on the development, manufacturing, and commercialization of generic medicines and biosimilars. Their offerings include finished dosage forms of small molecule pharmaceuticals, often supplied to other businesses. Additionally, the company provides protein-based and other biotechnology-derived products, along with specialized biotechnology manufacturing services. Sandoz also produces anti-infective compounds, specifically active pharmaceutical ingredients (APIs) and intermediates, with a strong emphasis on antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
Market snapshot
- Symbol
- SDZNY
- Price
- $84.32
- Day change
- -1.39%
- Market cap
- $36.4B
- P/E ratio
- 39.54x
- 52-week range
- 52.005-94.15
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
Recent news
- Generic drugmaker Sandoz files anti-dumping complaint about Chinese antibiotics imports
Swiss generic drugmaker Sandoz filed a draft anti-dumping complaint with the European Commission over Chinese imports of the antibiotic ingredient amoxicillin, part of the penicillin family, the company said on Thursday.
- Sandoz CEO Says Size of Weight-Loss Generics Market Is Unknown
Switzerland's Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.
Peer companies
Open Sandoz Group AG (SDZNY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.